Rosen Law Firm Reminds Tesla, Inc. Investors of Important

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
111
Rosen Law Firm Reminds Tesla, Inc. Investors of Important Deadline in First Filed Class Action – TSLA

NEW YORK, Nov. 21, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common shares of Tesla, Inc. (NASDAQ: TSLA ) from May 4, 2016 through October 6, 2017, inclusive (the “Class Period”) of the important December 11, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Tesla investors under the federal securities laws.

To join the Tesla class action, go to http://www.rosenlegal.com/cases-1218.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) contrary to defendants’ representations that Tesla was prepared for the launch of its Model 3 sedan, in reality, Tesla had severely inadequate inventory and was woefully unprepared to launch Model 3 sedan as anticipated; and (2) as a result, Tesla’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 11, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1218.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com .

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising.  Prior results do not guarantee a similar outcome.

Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY  10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 6

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 5

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading

Top 5 Most Recently Viewed Articles

Enanta Pharmaceuticals Highlights Fiscal Q1 2025 Performance

Updated Category News Views 188

Enanta Pharmaceuticals Reports Financial Highlights for Q1 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology firm, has revealed its financial results for the first fiscal quarter ending December 31, 2024. This quarter is seen as a crucial period for the company as it expands its innovative drug portfolio targeting viral and immunological...

Continue Reading
Friedman Industries Reports Impressive First Quarter Growth

Updated Category News Views 98

Friedman Industries Reports Significant First Quarter Growth Friedman Industries, Incorporated (NASDAQ/GS: FRD) has announced remarkable results for the first quarter of the fiscal year, showcasing a strong performance that has positioned the company favorably in the steel manufacturing sector. The results released highlight not only the growth in earnings but also an...

Continue Reading
From Doubt to Delicious: The Rise of Raising Cane's

Updated Category News Views 308

Overcoming Doubt: The Birth of Raising Cane's The journey of Raising Cane's is not just about chicken fingers; it's a story of perseverance. Founded by Todd Graves, the chain has become a testament to how challenges can fuel passion and success. Graves faced significant skepticism from those who thought the concept was flawed due to its limited menu. Motivation Behind...

Continue Reading
Understanding Japan's Impact on US Tech Stock Dynamics

Updated Category News Views 371

The Influence of Japan's Real Rates on US Markets The current landscape of the S&P 500 bull market has been subject to various influences, and surprisingly, one of the most significant factors is not a domestic recession in the US but rather Japan's extraordinarily negative real interest rates compared to those in the US. This insightful perspective comes from BCA...

Continue Reading
Ocean Ledger Secures Funding to Enhance Coastal Risk Solutions

Updated Category News Views 171

Ocean Ledger Secures Funding for Coastal Risk Management Ocean Ledger, a promising geospatial analytics startup, has recently completed a successful funding round, securing $900K to enhance its capabilities in coastal risk management. This investment is poised to support the development of innovative solutions aimed at forecasting coastal risks, benefitting various...

Continue Reading